ZNF385B mRNA表达下调是乳腺癌的独立预测因子

IF 2.6 4区 生物学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY
International Journal of Genomics Pub Date : 2021-02-03 eCollection Date: 2021-01-01 DOI:10.1155/2021/4301802
Ning Yan, Cong Liu, Fang Tian, Ling Wang, Yimin Wang, Zhaoying Yang, Yan Jiao, Miao He
{"title":"ZNF385B mRNA表达下调是乳腺癌的独立预测因子","authors":"Ning Yan,&nbsp;Cong Liu,&nbsp;Fang Tian,&nbsp;Ling Wang,&nbsp;Yimin Wang,&nbsp;Zhaoying Yang,&nbsp;Yan Jiao,&nbsp;Miao He","doi":"10.1155/2021/4301802","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>ZNF385B, a zinc finger protein, has been known as a potential biomarker in some neurological and hematological studies recently. Although numerous studies have demonstrated the potential function of zinc finger proteins in tumor progression, the effects of ZNF385B in breast cancer (BC) are less studied.</p><p><strong>Methods: </strong>The Oncomine database and \"ESurv\" tool were used to explore the differential expression of ZNF385B in pan-cancer. Furthermore, data of patients with BC were downloaded from The Cancer Genome Atlas (TCGA). The receiver operating characteristic (ROC) curve of ZNF385B expression was established to explore the diagnostic value of ZNF385B and to obtain the cut-off value of high or low ZNF385B expression in BC. The chi-square test as well as Fisher exact test was used for identification of the relationships between clinical features and ZNF385B expression. Furthermore, the effects of ZNF385B on BC patients' survival were evaluated by the Kaplan-Meier and Cox regression. Data from the Gene Expression Omnibus (GEO) database were employed to validate the results of TCGA. Protein expression of ZNF385B in BC patient specimens was detected by immunohistochemistry (IHC) staining.</p><p><strong>Results: </strong>ZNF385B expression was downregulated in most types of cancer including BC. Low ZNF385B expression was related with survival status, overall survival (OS), and recurrence of BC. ZNF385B had modest diagnostic value, which is indicated by the area under the ROC curve (AUC = 0.671). Patients with lower ZNF385B expression had shorter OS and RFS (relapse-free survival). It had been demonstrated that low ZNF385B expression represented independent prognostic value for OS and RFS by multivariate survival analysis. The similar results were verified by datasets from the GEO database as well. The protein expression of ZNF385B was decreased in patients' samples compared with adjacent tissues by IHC.</p><p><strong>Conclusions: </strong>Low ZNF385B expression was an independent predictor for worse prognosis of BC patients.</p>","PeriodicalId":13988,"journal":{"name":"International Journal of Genomics","volume":"2021 ","pages":"4301802"},"PeriodicalIF":2.6000,"publicationDate":"2021-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7876827/pdf/","citationCount":"2","resultStr":"{\"title\":\"Downregulated mRNA Expression of ZNF385B Is an Independent Predictor of Breast Cancer.\",\"authors\":\"Ning Yan,&nbsp;Cong Liu,&nbsp;Fang Tian,&nbsp;Ling Wang,&nbsp;Yimin Wang,&nbsp;Zhaoying Yang,&nbsp;Yan Jiao,&nbsp;Miao He\",\"doi\":\"10.1155/2021/4301802\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>ZNF385B, a zinc finger protein, has been known as a potential biomarker in some neurological and hematological studies recently. Although numerous studies have demonstrated the potential function of zinc finger proteins in tumor progression, the effects of ZNF385B in breast cancer (BC) are less studied.</p><p><strong>Methods: </strong>The Oncomine database and \\\"ESurv\\\" tool were used to explore the differential expression of ZNF385B in pan-cancer. Furthermore, data of patients with BC were downloaded from The Cancer Genome Atlas (TCGA). The receiver operating characteristic (ROC) curve of ZNF385B expression was established to explore the diagnostic value of ZNF385B and to obtain the cut-off value of high or low ZNF385B expression in BC. The chi-square test as well as Fisher exact test was used for identification of the relationships between clinical features and ZNF385B expression. Furthermore, the effects of ZNF385B on BC patients' survival were evaluated by the Kaplan-Meier and Cox regression. Data from the Gene Expression Omnibus (GEO) database were employed to validate the results of TCGA. Protein expression of ZNF385B in BC patient specimens was detected by immunohistochemistry (IHC) staining.</p><p><strong>Results: </strong>ZNF385B expression was downregulated in most types of cancer including BC. Low ZNF385B expression was related with survival status, overall survival (OS), and recurrence of BC. ZNF385B had modest diagnostic value, which is indicated by the area under the ROC curve (AUC = 0.671). Patients with lower ZNF385B expression had shorter OS and RFS (relapse-free survival). It had been demonstrated that low ZNF385B expression represented independent prognostic value for OS and RFS by multivariate survival analysis. The similar results were verified by datasets from the GEO database as well. The protein expression of ZNF385B was decreased in patients' samples compared with adjacent tissues by IHC.</p><p><strong>Conclusions: </strong>Low ZNF385B expression was an independent predictor for worse prognosis of BC patients.</p>\",\"PeriodicalId\":13988,\"journal\":{\"name\":\"International Journal of Genomics\",\"volume\":\"2021 \",\"pages\":\"4301802\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2021-02-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7876827/pdf/\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Genomics\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://doi.org/10.1155/2021/4301802\",\"RegionNum\":4,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Genomics","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1155/2021/4301802","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 2

摘要

背景:锌指蛋白ZNF385B是一种潜在的生物标志物,近年来在一些神经学和血液学研究中得到广泛应用。尽管大量研究已经证明锌指蛋白在肿瘤进展中的潜在功能,但ZNF385B在乳腺癌(BC)中的作用研究较少。方法:利用Oncomine数据库和“ESurv”工具研究ZNF385B在泛癌组织中的差异表达。此外,从癌症基因组图谱(TCGA)下载了BC患者的数据。建立ZNF385B表达的受试者工作特征(ROC)曲线,探讨ZNF385B的诊断价值,获得BC中ZNF385B高表达或低表达的临界值。采用卡方检验和Fisher精确检验鉴定临床特征与ZNF385B表达的关系。此外,通过Kaplan-Meier和Cox回归评估ZNF385B对BC患者生存的影响。采用基因表达综合数据库(Gene Expression Omnibus, GEO)中的数据验证TCGA的结果。免疫组织化学(IHC)染色检测BC患者标本中ZNF385B蛋白的表达。结果:ZNF385B在包括BC在内的大多数肿瘤中表达下调。ZNF385B低表达与BC的生存状态、总生存期(OS)和复发有关。ZNF385B具有中等诊断价值,由ROC曲线下面积(AUC = 0.671)可知。ZNF385B表达较低的患者OS和RFS(无复发生存期)较短。多变量生存分析表明,ZNF385B低表达对OS和RFS具有独立的预后价值。GEO数据库的数据集也验证了类似的结果。通过免疫组化,患者标本中ZNF385B蛋白表达较邻近组织降低。结论:ZNF385B低表达是BC患者预后较差的独立预测因子。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Downregulated mRNA Expression of ZNF385B Is an Independent Predictor of Breast Cancer.

Downregulated mRNA Expression of ZNF385B Is an Independent Predictor of Breast Cancer.

Downregulated mRNA Expression of ZNF385B Is an Independent Predictor of Breast Cancer.

Downregulated mRNA Expression of ZNF385B Is an Independent Predictor of Breast Cancer.

Background: ZNF385B, a zinc finger protein, has been known as a potential biomarker in some neurological and hematological studies recently. Although numerous studies have demonstrated the potential function of zinc finger proteins in tumor progression, the effects of ZNF385B in breast cancer (BC) are less studied.

Methods: The Oncomine database and "ESurv" tool were used to explore the differential expression of ZNF385B in pan-cancer. Furthermore, data of patients with BC were downloaded from The Cancer Genome Atlas (TCGA). The receiver operating characteristic (ROC) curve of ZNF385B expression was established to explore the diagnostic value of ZNF385B and to obtain the cut-off value of high or low ZNF385B expression in BC. The chi-square test as well as Fisher exact test was used for identification of the relationships between clinical features and ZNF385B expression. Furthermore, the effects of ZNF385B on BC patients' survival were evaluated by the Kaplan-Meier and Cox regression. Data from the Gene Expression Omnibus (GEO) database were employed to validate the results of TCGA. Protein expression of ZNF385B in BC patient specimens was detected by immunohistochemistry (IHC) staining.

Results: ZNF385B expression was downregulated in most types of cancer including BC. Low ZNF385B expression was related with survival status, overall survival (OS), and recurrence of BC. ZNF385B had modest diagnostic value, which is indicated by the area under the ROC curve (AUC = 0.671). Patients with lower ZNF385B expression had shorter OS and RFS (relapse-free survival). It had been demonstrated that low ZNF385B expression represented independent prognostic value for OS and RFS by multivariate survival analysis. The similar results were verified by datasets from the GEO database as well. The protein expression of ZNF385B was decreased in patients' samples compared with adjacent tissues by IHC.

Conclusions: Low ZNF385B expression was an independent predictor for worse prognosis of BC patients.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
International Journal of Genomics
International Journal of Genomics BIOCHEMISTRY & MOLECULAR BIOLOGY-BIOTECHNOLOGY & APPLIED MICROBIOLOGY
CiteScore
5.40
自引率
0.00%
发文量
33
审稿时长
17 weeks
期刊介绍: International Journal of Genomics is a peer-reviewed, Open Access journal that publishes research articles as well as review articles in all areas of genome-scale analysis. Topics covered by the journal include, but are not limited to: bioinformatics, clinical genomics, disease genomics, epigenomics, evolutionary genomics, functional genomics, genome engineering, and synthetic genomics.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信